Hepatitis A vaccination in patients with chronic liver disease: to screen or not to screen?

Rothstein, Kenneth D.
July 2002
American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1590
Academic Journal
No abstract available.


Related Articles

  • Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. Dumot, John A.; Barnes, David S.; Younossi, Zobair; Gordon, Steven M.; Avery, Robin K.; Domen, Ronald E.; Henderson, J. Michael; Carey, William D. // American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1601 

    OBJECTIVE: Hepatitis A can cause decompensation and death in patients with previous liver injury. The hepatitis A vaccine is recommended for patients with chronic liver disease. The aim of this study was to screen, immunize, and measure the safety and antibody response of the hepatitis A vaccine...

  • Hepatoma and chronic liver disease from maternally transmitted hepatitis B infection.  // Journal of Medical Screening;Mar1998, Vol. 5 Issue 1, p54 

    The article reports on the lifetime risk of death from hepatoma or chronic liver disease from maternally transmitted hepatitis B infection. It discusses the prevalence hepatitis B carriers in the antenatal population, its screening tests, the use of recombinant vaccine for intervention and the...

  • Hepatitis A, B vaccinations low in patients with chronic liver disease, diabetes. Friedman, Lawrence S. // Infectious Disease News;Jun2011, Vol. 24 Issue 6, p8 

    The article reports on a study which revealed that hepatitis A and hepatitis B vaccinations are low in patients with chronic liver disease and in those with type 2 diabetes.

  • Evaluation of the Hepatitis C Virus–Infected Patient: The Initial Encounter. Bräu, Norbert // Clinical Infectious Diseases;Mar2013, Vol. 56 Issue 6, p853 

    Chronic hepatitis C is a major cause of mortality from liver disease, but cure rates from antiviral treatments are improving. As expanded hepatitis C virus screening identifies more patients, infectious diseases physicians have a unique opportunity to be part of the cure.Deaths from hepatitis C...

  • Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Duncan, Marten; Hirota, William K.; Tsuchida, Amy // American Journal of Gastroenterology;Jul2002, Vol. 97 Issue 7, p1792 

    OBJECTIVES:There are few prospective studies estimating the prevalence of hepatitis A in chronic liver disease patients. Furthermore, there are minimal cost-comparative data as to whether or not screening for hepatitis A exposure before immunization is an effective fiscal strategy. The...

  • Nonalcoholic Fatty Liver Disease in Chronic Hepatitis C. Patrick, Lyn // Townsend Letter;Apr2014, Issue 369, p67 

    The article addresses the question of whether all patients with diagnosed nonalcoholic fatty liver disease (NFLD) should be screened for chronic hepatitis C and whether all chronic hepatitis C patients should be screened for NASH (nonalcoholic steatotic hepatitis). In indicates an increased...

  • ATL>The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Jacobs, R. Jake; Koff, Raymond S.; Meyerhoff, Allen S. // American Journal of Gastroenterology;Feb2002, Vol. 97 Issue 2, p427 

    OBJECTIVES:Although hepatitis A vaccination is recommended for persons with chronic liver disease, the cost-effectiveness of vaccinating patients with chronic hepatitis C virus has not been extensively studied. We evaluated its costs and benefits.METHODS:A Markov model was used to assess...

  • Hepatitis C: Diagnosis and Treatment. WILKINS, THAD; MALCOLM, JENNIFER K.; SCHADE, ROBERT R. // American Family Physician;6/1/2010, Vol. 81 Issue 11, p1351 

    Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk...

  • Integrating Viral Hepatitis Screening and Prevention Services into an Urban Chemical Dependency Treatment Facility for American Indians and Alaska Natives. Huffman, Shelly; Brucker, Rachel; Redd, John T.; Taualii, Maile; Town, Cecile M.; Castor, Mei L.; Tetrick, Crystal C.; Forquera, Ralph; Buffington, Joanna // Journal of Health Disparities Research & Practice;Summer2011, Vol. 5 Issue 1, p32 

    American Indian/Alaska Natives (AI/AN) patients at an urban residential chemical dependency treatment center participated in a viral hepatitis prevention project. Project activities integrated into patients' treatment programs included viral hepatitis and human immunodeficiency virus (HIV) risk...

  • Hepatitis A vaccine tags on new indication.  // Drug Topics;7/7/97, Vol. 141 Issue 13, p7 

    States that SmithKline Beecham's Havrix (hepatitis A vaccine inactivated), has been approved for active immunization against the hepatitis A virus in patients with chronic liver disease. Information on how the hepatitis A virus is spread.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics